Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Gains from Sales and Divestitures (2019 - 2022)

Cue Biopharma's Gains from Sales and Divestitures history spans 4 years, with the latest figure at $98335.0 for Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures fell 25.32% year-over-year to $98335.0; the TTM value through Dec 2022 reached $98335.0, down 25.32%, while the annual FY2022 figure was $98335.0, 25.32% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2022 was $98335.0 at Cue Biopharma, roughly flat from $98335.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $131667.0 in Q4 2021 and bottomed at $16666.0 in Q1 2020.
  • The 4-year median for Gains from Sales and Divestitures is $74166.5 (2020), against an average of $64444.5.
  • The largest YoY upside for Gains from Sales and Divestitures was 450.03% in 2022 against a maximum downside of 25.32% in 2022.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $33333.0 in 2019, then soared by 70.0% to $56665.0 in 2020, then surged by 132.36% to $131667.0 in 2021, then fell by 25.32% to $98335.0 in 2022.
  • Per Business Quant, the three most recent readings for CUE's Gains from Sales and Divestitures are $98335.0 (Q4 2022), $98335.0 (Q3 2022), and $91668.0 (Q2 2022).